Literature DB >> 10832733

Abnormal immune function in vivo in a murine model of lysosomal storage disease.

T M Daly1, R G Lorenz, M S Sands.   

Abstract

Lysosomal storage diseases are a class of inborn errors of metabolism that lead to widespread disease in multiple tissues. The murine model of mucopolysaccharidosis type VII (MPS VII) closely parallels the human syndrome and has been extensively used to investigate the natural history and therapeutic strategies for lysosomal storage diseases in general. Here we demonstrate a previously undescribed immune defect in the MPS VII mouse. Although the normal populations of cells are present in lymph nodes of these mice, MPS VII mice show a blunted T cell proliferative response and decreased antibody production after immunization with antigens. One mechanism of this defect is ineffective processing of protein antigens, as responses to peptide antigens are normal. This phenotype is presumably caused by the lysosomal disorder, as the defect can be corrected in vivo by direct enzyme replacement therapy. These findings have implications for the use of this animal model, and may have clinical significance for other, more-common lysosomal storage diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10832733     DOI: 10.1203/00006450-200006000-00012

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  10 in total

Review 1.  Mucopolysaccharide diseases: a complex interplay between neuroinflammation, microglial activation and adaptive immunity.

Authors:  Louise D Archer; Kia J Langford-Smith; Brian W Bigger; James E Fildes
Journal:  J Inherit Metab Dis       Date:  2013-05-08       Impact factor: 4.982

2.  A Hitchhiker's guide to the blood-brain barrier: in trans delivery of a therapeutic enzyme.

Authors:  Mark S Sands
Journal:  Mol Ther       Date:  2014-03       Impact factor: 11.454

3.  Active site mutant transgene confers tolerance to human beta-glucuronidase without affecting the phenotype of MPS VII mice.

Authors:  W S Sly; C Vogler; J H Grubb; M Zhou; J Jiang; X Y Zhou; S Tomatsu; Y Bi; E M Snella
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

4.  Production of MPS VII mouse (Gus(tm(hE540A x mE536A)Sly)) doubly tolerant to human and mouse beta-glucuronidase.

Authors:  Shunji Tomatsu; Koji O Orii; Carole Vogler; Jeffrey H Grubb; Elizabeth M Snella; Monica Gutierrez; Tatiana Dieter; Christopher C Holden; Kazuko Sukegawa; Tadao Orii; Naomi Kondo; William S Sly
Journal:  Hum Mol Genet       Date:  2003-05-01       Impact factor: 6.150

Review 5.  Combination therapies for lysosomal storage disease: is the whole greater than the sum of its parts?

Authors:  Jacqueline A Hawkins-Salsbury; Adarsh S Reddy; Mark S Sands
Journal:  Hum Mol Genet       Date:  2011-03-19       Impact factor: 6.150

6.  Preferential Coupling of the NAADP Pathway to Exocytosis in T-Cells.

Authors:  Lianne C Davis; Frances M Platt; Antony Galione
Journal:  Messenger (Los Angel)       Date:  2015-06

7.  Promising CNS-directed enzyme replacement therapy for lysosomal storage diseases.

Authors:  Shannon L Macauley; Mark S Sands
Journal:  Exp Neurol       Date:  2009-04-08       Impact factor: 5.330

8.  Mannose 6 phosphorylation of lysosomal enzymes controls B cell functions.

Authors:  Takanobu Otomo; Michaela Schweizer; Katrin Kollmann; Valéa Schumacher; Nicole Muschol; Eva Tolosa; Hans-Willi Mittrücker; Thomas Braulke
Journal:  J Cell Biol       Date:  2015-01-19       Impact factor: 10.539

9.  Signatures of Altered Gene Expression in Dorsal Root Ganglia of a Fabry Disease Mouse Model.

Authors:  Kai K Kummer; Theodora Kalpachidou; Michaela Kress; Michiel Langeslag
Journal:  Front Mol Neurosci       Date:  2018-01-25       Impact factor: 5.639

10.  Altered Gene Expression in Prefrontal Cortex of a Fabry Disease Mouse Model.

Authors:  Kai K Kummer; Theodora Kalpachidou; Miodrag Mitrić; Michiel Langeslag; Michaela Kress
Journal:  Front Mol Neurosci       Date:  2018-06-25       Impact factor: 5.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.